Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...
NEW YORK, NY / ACCESSWIRE / November 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible ...
The 22nd Annual Winter Lung Cancer Conference® will explore advances in neoadjuvant/adjuvant therapies. The FDA has approved Obe-cel for R/R B-ALL, and new treatments in SCLC, lurbinectedin and ...
ATTENTION ESSA Pharma Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights ...
Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with me ...
Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback